3Musti M,Kettunen E,Dragonieri S,et al.Cytogenetic and molecular genetic changes in malignant mesothelioma[J].Cancer Genet Cytogenet,2006,170(1):9-15.
4Taniguchi T,Karnan S,Fukui T.Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromasomal alteration regions including JUN amplification on 1p32[J].Cancer Sci,2007,98(3):438-446.
5Attanoos RL,Allen TC,Borczuk AC.Advances in surgical pathology:mesothelioma[M].Philadelpia PA:LWW Press,2013.143-153,175-181.
6Nemoto H,Tate G,Kishimoto K.Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum[J].Cancer Genet,2012,205(11):594-598.
7Dacic S,Kothmaier H,Land S.Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas[J].Virchows Arch,2008,453(6):627-635.
8Kobayashi N,Toyooka S,Yanai H.Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma[J].Lung Cancer,2008,62(1):120-125.
9Husain AN,Golby T,Ordonez N.Guidelines for pathologic diagnosis of malignant mesothelioma:2012 update of the consensus statement from the international mesothelioma interest group[J].Arch Pathol Lab Med,2013,137(5):647-667.
10Kobashi Y,Matsushima T,Irei T.Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma[J].Respirology,2005,10(5):660-665.
